Treatment Outcomes and Adherence to Treatment in Patients with Immune Thrombocytopenia in Two Ethiopian Teaching Hospitals: a Retrospective Cohort Study

Overview

Journal Sci Rep

Specialty Science

Date 2024 May 24

PMID 38789461

Authors

Dessale Abate Beyene

Eskinder Ayalew Sisay

Atalay Mulu Fentie

Amha Gebremedhin

Affiliations

Soon will be listed here.

Abstract

The treatment of immune thrombocytopenia (ITP) is challenging and treatment outcomes depend on numerous unknown and patient-specific factors. Corticosteroids are the cornerstone of ITP treatment, but they are associated with many side effects. In this retrospective cohort study, treatment outcomes and treatment adherence in patients with ITP were investigated in 214 ITP patients from November 15, 2022 to March 15, 2023. Multinomial regression analysis models were used to identify predictive factors for treatment outcomes. A p value of less than 0.05 was considered statistically significant. Most study participants were female 161 (75.5%), and the majority 172 (80.4%) of them were taking prednisolone only. In terms of treatment adherence, 178 (83.2%) of the study participants adhered well to their ITP medications. The complete response rate at 3 months was 139 (65.0%). Predictive factors for partial response were increased negative impact of ITP on health-related quality of life (AOR = 1.221, 95% CI 1.096-1.360), being treated at Tikur Abessa Sepcialazed Hospital (AOR = 0.431, 95% CI 0.197-0.941) and the presence of heavy menstrual bleeding (AOR = 2.255, 95% CI 0.925-5.497) compared to patients with complete response. Hepatitis B virus-infected ITP patients (AOR = 0.052, 95% CI 0.004-0.621) were also a predictive factor for no response compared to complete response.

Citing Articles

Patient, family, and community factors associated with medication adherence among people with hypertension or diabetes: A cross-sectional analysis.

Wu Y, Xiong S, Zhu G, Chen X, Zhang M, Gong E Explor Res Clin Soc Pharm. 2024; 15:100482.

PMID: 39157069 PMC: 11328030. DOI: 10.1016/j.rcsop.2024.100482.

References

Mashhadi M, Kaykhaei M, Sepehri Z, Miri-Moghaddam E . Single course of high dose dexamethasone is more effective than conventional prednisolone therapy in the treatment of primary newly diagnosed immune thrombocytopenia. Daru. 2013; 20(1):7. PMC: 3557140. DOI: 10.1186/2008-2231-20-7. View

Chugh S, Darvish-Kazem S, Lim W, Crowther M, Ghanima W, Wang G . Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol. 2015; 2(2):e75-81. DOI: 10.1016/S2352-3026(15)00003-4. View

Kashiwagi H, Tomiyama Y . Pathophysiology and management of primary immune thrombocytopenia. Int J Hematol. 2013; 98(1):24-33. DOI: 10.1007/s12185-013-1370-4. View

Grimaldi-Bensouda L, Nordon C, Michel M, Viallard J, Adoue D, Magy-Bertrand N . Immune thrombocytopenia in adults: a prospective cohort study of clinical features and predictors of outcome. Haematologica. 2016; 101(9):1039-45. PMC: 5060020. DOI: 10.3324/haematol.2016.146373. View

Gernsheimer T . Epidemiology and pathophysiology of immune thrombocytopenic purpura. Eur J Haematol Suppl. 2008; (69):3-8. DOI: 10.1111/j.1600-0609.2007.00998.x. View

Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J . Outpatient Management of Patients with Immune Thrombocytopenia (ITP) by Hematologists 1995-2014. Oncol Res Treat. 2016; 39(1-2):41-4. DOI: 10.1159/000442769. View

Rajan S, Espina B, Liebman H . Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura. Br J Haematol. 2005; 129(6):818-24. DOI: 10.1111/j.1365-2141.2005.05542.x. View

Trotter P, Hill Q . Immune thrombocytopenia: improving quality of life and patient outcomes. Patient Relat Outcome Meas. 2018; 9:369-384. PMC: 6267629. DOI: 10.2147/PROM.S140932. View

Kurata Y, Fujimura K, Kuwana M, Tomiyama Y, Murata M . Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review. Int J Hematol. 2011; 93(3):329-335. DOI: 10.1007/s12185-011-0791-1. View

10.

Chiao E, Engels E, Kramer J, Pietz K, Henderson L, Giordano T . Risk of immune thrombocytopenic purpura and autoimmune hemolytic anemia among 120 908 US veterans with hepatitis C virus infection. Arch Intern Med. 2009; 169(4):357-63. PMC: 2782638. DOI: 10.1001/archinternmed.2008.576. View

11.

Jaime-Perez J, Ramos-Davila E, Aguilar-Calderon P, Jimenez-Castillo R, Gomez-Almaguer D . Diagnoses, Outcomes, and Chronicity Predictors of Patients with Secondary Immune Thrombocytopenia: Ten-Year Data from a Hematology Referral Center. Rev Invest Clin. 2020; 73(1):031-038. DOI: 10.24875/RIC.20000214. View

12.

Grainger J, Young N, Blanchette V, Klaassen R . Quality of life in immune thrombocytopenia following treatment. Arch Dis Child. 2013; 98(11):895-7. DOI: 10.1136/archdischild-2013-303784. View

13.

Kewan T, Gunaratne T, Mushtaq K, Alayan D, Daw H, Haddad A . Outcomes and management of immune thrombocytopenia secondary to COVID-19: Cleveland clinic experience. Transfusion. 2021; 61(7):2014-2018. PMC: 8250532. DOI: 10.1111/trf.16368. View

14.

Terrell D, Neunert C, Cooper N, Heitink-Polle K, Kruse C, Imbach P . Immune Thrombocytopenia (ITP): Current Limitations in Patient Management. Medicina (Kaunas). 2020; 56(12). PMC: 7761470. DOI: 10.3390/medicina56120667. View

15.

Chang H, Tang T, Hung Y, Li P, Kuo M, Wu J . Immune thrombocytopenia: Effectiveness of frontline steroids and comparison of azathioprine, splenectomy, and rituximab as second-line treatment. Eur J Haematol. 2018; 101(4):549-555. DOI: 10.1111/ejh.13144. View

16.

Palau J, Sancho E, Herrera M, Sanchez S, Mingot M, Upegui R . Characteristics and management of primary and other immune thrombocytopenias: Spanish registry study. Hematology. 2017; 22(8):484-492. DOI: 10.1080/10245332.2017.1311442. View

17.

Snyder C, Mathias S, Cella D, Isitt J, Wu A, Young J . Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey. Curr Med Res Opin. 2008; 24(10):2767-76. DOI: 10.1185/03007990802377461. View

18.

Tjonnfjord E, Holme P, Darne B, Khelif A, Waage A, Michel M . Long-term outcomes of patients treated with rituximab as second-line treatment for adult immune thrombocytopenia - Follow-up of the RITP study. Br J Haematol. 2020; 191(3):460-465. DOI: 10.1111/bjh.16672. View

19.

Marini I, Zlamal J, Faul C, Holzer U, Hammer S, Pelzl L . Autoantibody-mediated desialylation impairs human thrombopoiesis and platelet lifespan. Haematologica. 2019; 106(1):196-207. PMC: 7776251. DOI: 10.3324/haematol.2019.236117. View

20.

Neunert C, Terrell D, Arnold D, Buchanan G, Cines D, Cooper N . American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019; 3(23):3829-3866. PMC: 6963252. DOI: 10.1182/bloodadvances.2019000966. View